Prelude Therapeutics Incorporated (PRLD) Tops Q1 EPS by 9c

Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q1 EPS of ($0.58), $0.09 better than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• SanDisk upgraded at JPMorgan after investor day; shares climb